Purchase this article with an account.
Seung Jae Lee, Youngdon Kim, Haksu Kyung, ; Difference of intraocular pressure lowering effects among 3 Prostaglandin analogs for korean glaucoma and ocular hypertension patients. Invest. Ophthalmol. Vis. Sci. 2014;55(13):552.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare intraocular pressure(IOP) lowering effects of tafluprost, travoprost, bimatoprost respectively for korean glaucoma patients.
Seventy eight patients, 147 eyes, diagnosed with normal tension glaucoma(NTG), ocular hypertension(OHT), or primary open-angle glaucoma(POAG), received 0.0015% tafluprost, 0.004% travoprost or 0.01% bimatoprost respectively once daily. We compared and analyzed IOP and the change of IOP at baseline, after a week and after a month.
Of all 147 eyes, there were 72 eyes of NTG, 35 eyes of OHT, 7 eyes of POAG, and 10 eyes of other glaucoma in tafluprost group. There were 24 eyes of NTG, 2 eyes of POAG, and 7 eyes of other glaucoma in travoprost group. There were 14 eyes of NTG, 4 eyes of POAG, and 2 eyes of other glaucoma in bimatoprost group. In tafluprost group, the average IOP was 16.2 ± 3.2 mmHg at baseline, 12.5 ± 2.6 mmHg (p<0.0001) after 1 week, and 12.4 ± 2.8 mmHg(p<0.0001) after 1 month. In travoprost group, the average IOP was 15.1 ± 2.2 mmHg at baseline, 11.0 ± 2.7 mmHg (p<0.0001) after 1 week, and 12.7 ± 2.2 mmHg (p=0.001) after 1 month. In bimatoprost group the IOP was 16.5 ± 2.8 mmHg at baseline, 11.9 ± 2.2mmHg(p<0.0001) after 1 week, and 13.7 ± 3.5 mmHg (p<0.0001) after 1 month, which all showed statistically significant IOP reduction. No meaningful correlation bewteen baseline IOP and the change of IOP was shown in the travoprost group (p=0.191, r=0.234) and bimatoprost group (p=0.395, r=0.201). However in tafluprost group (p=0.03, r=0.305), as the baseline IOP was higher, the change of IOP was higher significantly.
Tafluprost, travoprost and bimatoprost were all effective in IOP lowering effects until one month for korean glaucoma and ocular hypertension patients. Travoprost and bimatoprost showed consistent IOP reduction regardless of baseline IOP. Otherwise in tafluprost group, as the baseline IOP was higher, the change of IOP was higher significantly.
This PDF is available to Subscribers Only